Hydrocortisone May Lower Severe CAP Mortality - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Hydrocortisone May Lower Severe CAP Mortality

Network meta-analysis suggests hydrocortisone may offer mortality and ventilation benefits, although evidence certainty remained low.

  • By

  • Andrea Surnit

  • May 11, 2026

  • 3 min

Share

Objective:

To evaluate the impact of different corticosteroids on mortality in patients with severe community-acquired pneumonia (CAP).

Key Findings:
  • Hydrocortisone was associated with a relative reduction of approximately 65% in all-cause mortality risk compared to placebo.
Interpretation:

Hydrocortisone may be more effective than other corticosteroids in reducing mortality and mechanical ventilation needs in severe CAP, but findings are based on indirect comparisons and should be interpreted with caution.

Limitations:
  • Reliance on indirect comparisons due to all studies comparing corticosteroids with placebo.
  • Low certainty of evidence due to imprecision, heterogeneity, and variability in study designs, including definitions of severe CAP and corticosteroid dosing strategies.
  • Limited statistical power for subgroup analyses.
Conclusion:

While hydrocortisone shows promise in reducing mortality in severe CAP, the evidence is not robust enough to change current treatment guidelines, and further research is needed.

Original Source(s)

Hydrocortisone May Lower Severe CAP Mortality

  • by Andrea Surnit

  • May 11, 2026

Related Content

First HIV-Positive-to-HIV-Positive Lung Transplant Reported

The procedure was performed under a HOPE Act research protocol at an NYU Langone Health center the institution said is among the limited number of US transplant centers equipped and approved to perform HOPE lung transplants.

FDA Monthly Preview: Key August Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Shorter TB Regimens Advance Care

Review highlights shorter tuberculosis regimens while warning that rising bedaquiline resistance may threaten future progress.